nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0213	0.0213	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0209	0.0209	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0207	0.0207	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.0188	0.0188	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.0183	0.0183	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.0182	0.0182	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0179	0.0179	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0153	0.0153	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.015	0.015	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0148	0.0148	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0145	0.0145	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.0139	0.0139	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.0136	0.0136	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.0131	0.0131	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0128	0.0128	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0127	0.0127	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0124	0.0124	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.0119	0.0119	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.0118	0.0118	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0117	0.0117	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.0114	0.0114	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.0112	0.0112	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.0111	0.0111	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.0108	0.0108	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.0106	0.0106	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.0104	0.0104	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.0103	0.0103	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.0101	0.0101	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00996	0.00996	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00977	0.00977	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00976	0.00976	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.0096	0.0096	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00948	0.00948	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00945	0.00945	CbGpPWpGaD
Bosentan—EDNRB—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00934	0.00934	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00906	0.00906	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00888	0.00888	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00883	0.00883	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00842	0.00842	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00839	0.00839	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00835	0.00835	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00826	0.00826	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00816	0.00816	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00802	0.00802	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00792	0.00792	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00786	0.00786	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00776	0.00776	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.0077	0.0077	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00768	0.00768	CbGpPWpGaD
Bosentan—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00762	0.00762	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00762	0.00762	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00744	0.00744	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00738	0.00738	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00731	0.00731	CbGpPWpGaD
Bosentan—EDNRB—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00722	0.00722	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00722	0.00722	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00722	0.00722	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00714	0.00714	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.007	0.007	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00699	0.00699	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00687	0.00687	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00678	0.00678	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00676	0.00676	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00673	0.00673	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00668	0.00668	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00632	0.00632	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00629	0.00629	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00619	0.00619	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00598	0.00598	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00591	0.00591	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00563	0.00563	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00551	0.00551	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.0055	0.0055	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00534	0.00534	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00532	0.00532	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00523	0.00523	CbGpPWpGaD
Bosentan—EDNRA—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00517	0.00517	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00517	0.00517	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00511	0.00511	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00501	0.00501	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00491	0.00491	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00485	0.00485	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00481	0.00481	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00471	0.00471	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00467	0.00467	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.0045	0.0045	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00443	0.00443	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00434	0.00434	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00424	0.00424	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00422	0.00422	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.0042	0.0042	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00413	0.00413	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00413	0.00413	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00408	0.00408	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00405	0.00405	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00394	0.00394	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00382	0.00382	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00382	0.00382	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.0038	0.0038	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00375	0.00375	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.0037	0.0037	CbGpPWpGaD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00355	0.00355	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00351	0.00351	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00347	0.00347	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00345	0.00345	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00337	0.00337	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00334	0.00334	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00311	0.00311	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00303	0.00303	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00302	0.00302	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00301	0.00301	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00296	0.00296	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00296	0.00296	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00292	0.00292	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.0029	0.0029	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00286	0.00286	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00282	0.00282	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00273	0.00273	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00272	0.00272	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00268	0.00268	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00266	0.00266	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00265	0.00265	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.0025	0.0025	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00247	0.00247	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00242	0.00242	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00234	0.00234	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00233	0.00233	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00233	0.00233	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00225	0.00225	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00222	0.00222	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00219	0.00219	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00205	0.00205	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00204	0.00204	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00191	0.00191	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.0019	0.0019	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00189	0.00189	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00187	0.00187	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00179	0.00179	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00173	0.00173	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00167	0.00167	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00161	0.00161	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00161	0.00161	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00161	0.00161	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00159	0.00159	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00158	0.00158	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00157	0.00157	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00147	0.00147	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00146	0.00146	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00143	0.00143	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00128	0.00128	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00125	0.00125	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00124	0.00124	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00124	0.00124	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00122	0.00122	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00102	0.00102	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—COMT—attention deficit hyperactivity disorder	0.000973	0.000973	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000966	0.000966	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000937	0.000937	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000777	0.000777	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000757	0.000757	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000541	0.000541	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000536	0.000536	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000536	0.000536	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000527	0.000527	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000512	0.000512	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00049	0.00049	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000429	0.000429	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—EP300—attention deficit hyperactivity disorder	0.000417	0.000417	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000408	0.000408	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000354	0.000354	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000354	0.000354	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000348	0.000348	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000325	0.000325	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000323	0.000323	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000323	0.000323	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000313	0.000313	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000283	0.000283	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000269	0.000269	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000214	0.000214	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000213	0.000213	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	0.000139	0.000139	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	9.19e-05	9.19e-05	CbGpPWpGaD
